Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Kinase Fusion Inhibition in Melanoma
NCT02587650Phase 2Terminated
- Sponsor
- University of California, San Francisco
- Start
- Mar 2015
- Primary completion
- Jul 2018
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label trial of capmatinib, ceritinib, regorafenib and entrectinib in melanoma (4 arms), sponsored by University of California, San Francisco. Primary endpoint: Confirmed Overall Response Rate at 24 weeks. Started Mar 2015; status: terminated.
02
Drugs
capmatinibceritinibregorafenibentrectinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02587650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02587650.